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Abstract
Background—Immunotherapy for peanut allergy may be limited by the risk of adverse
reactions.
Objective—To investigate the safety and immunologic effects of a vaccine containing modified
peanut proteins.
Methods—This was a Phase 1 trial of EMP-123, a rectally administered suspension of
recombinant Ara h 1, Ara h 2 and Ara h 3, modified by amino acid substitutions at major IgE
binding epitopes, encapsulated in heat/phenol killed E. coli. Five healthy adults were treated with
4 weekly escalating doses after which 10 peanut allergic adults received weekly dose escalations
over 10 weeks from 10mcg to 3063mcg, followed by 3 biweekly doses of 3063 mcg.
Results—There were no significant adverse effects in the healthy volunteers. Of the 10 peanut
allergic subjects [4 with intermittent asthma, median peanut-IgE 33.3kUA/L (7.2–120.2), median
peanutskin prick test wheal 11.3mm (6.5–18)], 4 experienced no symptoms, one had mild rectal
symptoms, and the remaining 5 experienced adverse reactions preventing completion of dosing.
Two were categorized as mild but the remaining three were more severe, including one moderate
reaction and two anaphylactic reactions. Baseline peanut IgE was significantly higher in the 5
reactive subjects (median 82.4 versus 17.2kUA/L, p=0.032), as was baseline anti-Ara h 2 IgE (43.3
versus 8.3, p=0.036). Peanut skin test titration and basophil activation (at a single dilution) were
significantly reduced after treatment but no significant changes were detected for total IgE, peanut
IgE, or peanut IgG4.
Conclusions—Rectal administration of EMP-123 resulted in frequent adverse reactions,
including severe allergic reactions in 20%.
Corresponding Author: Robert A. Wood, MD, CMSC 1102 Johns Hopkins Hospital, 600 North Wolfe St, Baltimore, MD 21287,
rwood@jhmi.edu, Tel: 410-955-5883, Fax: 410-955-0229.
*Drs. Wood and Sicherer contributed equally to this manuscript
Statement of Author Contributions:
Drs. Wood and Sicherer contributed to protocol development, conducted the clinical trial, and participated in analyses and writing of
the manuscript. Drs. Lindblad and Stablein and Ms. Henning contributed to protocol development, participated in analyses and writing
of the manuscript. Drs. Burks, Sampson, and Grishin participated in analyses and writing of the manuscript.
NIH Public Access
Author Manuscript
Allergy. Author manuscript; available in PMC 2014 June 01.
Published in final edited form as:














Peanut allergy is increasingly prevalent, potentially fatal, and significantly impacts quality
of life (1–4). Current treatment relies on strict dietary avoidance and ready access to
injectable epinephrine. Traditional subcutaneous immunotherapy has proven unsafe for
peanut allergy (5) and although oral and sublingual immunotherapy have shown some
promise for peanut and other food allergens (6–9), these approaches have the potential for
significant adverse reactions (10–13).
Given the risks of administering intact food allergen to highly allergic patients, research
efforts have focused on the development of methods to render allergens less likely to induce
adverse IgE-mediated reactions, while still maintaining – or even enhancing – the potential
to induce tolerance (6). These approaches include immunotolerant peptides (14), engineered
recombinant proteins (15), plasmid DNA (16–17), and immunostimulatory sequences (18),
among others. Another variation on this theme, which was the focus of this trial, utilizes
mutated recombinant proteins administered within heat-killed Escherichia coli, with the
intent of both reducing clinical reactivity and generating maximal tolerogenic immune
responses. The potential utility of this vaccine, comprised of heat/phenol killed, E. coli-
encapsulated, recombinant Modified Peanut proteins Ara h 1, Ara h 2, and Ara h 3,
(EMP-123), is supported by murine studies in which rectal administration of EMP-123
appeared safe and potentially effective (19). This Phase 1 study was conducted to assess the




EMP-123 (Allertein Therapeutics, LLC) is a rectally administered vaccine consisting of
three recombinant modified peanut antigens encapsulated within heat/phenol inactivated E.
coli. Specifically, three recombinant modified peanut proteins (Ara h 1, Ara h 2, and Ara h
3) were modified by amino acid substitutions to disrupt common IgE binding sites as
previously described (20–21). These modified proteins are then separately expressed in E.
coli strain BLR(DE3), and the E. coli are subsequently killed using heat and phenol. The
expressed proteins remain encapsulated within the dead E. coli. The three resulting whole-
cell suspensions (EMP-1, EMP-2, and EMP-3; i.e., three drug substances) are combined
approximately 1 (Ara h 1) : 3.2 (Ara h 2) : 2.9 (Ara h 3) based on the intracellular
recombinant protein content of the recombinant modified proteins in phosphate buffered
saline (PBS), 10% glycerol, 0.5% phenol, and 0.5% hydroxypropyl methylcellulose
(HPMC) to form the drug product (EMP-123).
Subject Enrollment and Dosing Schema
The study was conducted in two phases, with an initial cohort of 5 healthy volunteers
followed by 10 peanut allergic subjects (Supplemental Figure 1). Subjects were 18 to 50
years of age with no history of severe anaphylaxis. The healthy volunteers had to ingest
peanut regularly, have no asthma history, and have negative skin prick tests (SPT, <3 mm
wheal) and specific IgE (<0.35 kUA/L, ImmunoCAP, Phadia, Uppsula, Sweden) to peanut.
The study was conducted under an Investigational New Drug application from the FDA,
with approval from the NIAID Data Safety Monitoring Board, the investigational review
boards of Mount Sinai and Johns Hopkins, and the NIH Recombinant DNA Advisory
Committee.
The healthy volunteers received four escalating doses of study product as a rectal suspension
on a weekly basis to achieve the maximum study dose, containing 3,063 µg of total modified
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peanut protein delivered rectally as a 7 ml suspension (Supplemental Figure 1). Each dose
was administered with a 2 hour observation and subjects maintained a home diary to record
any symptoms between visits, as well as weekly telephone interviews for 4 weeks after the
last dose.
The second phase of the study enrolled 10 peanut allergic subjects who were required to
have a convincing clinical history of peanut allergy, with the development of symptoms
(e.g., urticaria, flushing, rhinorrhea and sneezing, throat tightness or hoarseness, wheezing,
vomiting) within minutes to 2 hours of ingestion. Additionally, a positive peanut skin prick
test (SPT >5 mm wheal) and specific IgE (> 5 kUA/L) were required. Baseline oral food
challenges were not done for ethical reasons given that this was a Phase 1 study. Asthmatic
subjects could not be more than mild intermittent in severity. These subjects received
weekly dose escalations for 10 weeks to the maximum study dose, which was then
administered biweekly for 6 weeks (Supplemental Figure 1). If adverse reactions occurred,
only a single repeat dose or dose reduction was permitted. Dosing was not continued beyond
13 doses or 16 weeks, and the dose was not escalated beyond the 3,063 µg maximum study
dose. Each dose was administered under observation and subjects were monitored for a
minimum of 2 hours. Each dosing visit was followed with a telephone interview on the
following day and subjects maintained a home diary between visits. After the final dose,
weekly telephone calls were conducted for 4 weeks when a final study visit was completed.
Telephone interviews were also conducted 1, 2, 3 and 6 months after the last visit.
Study Objectives
The primary objective of this study was to assess the safety of rectally administered
EMP-123, first in healthy volunteers and then in 10 peanut allergic subjects. The primary
outcome measure was the percentage of subjects who successfully completed dosing with no
more than mild symptoms. The highest dose that ≥50% of the allergic subjects tolerated with
no more than mild symptoms, and at which no subjects experienced severe symptoms, was
the pre-defined maximum dose limit.
Secondary outcome measures included the rate of all serious and overall adverse events, the
rate of desensitization (as determined by peanut endpoint SPT titration in peanut allergic
subjects pre- and post-treatment), and changes in basophil activation and peanut-specific IgE
and IgG4. Additional post-hoc analyses were undertaken to explore IgE binding to the study
product pre- and post-treatment.
Laboratory Methods
Serologic Studies—Total IgE and peanut-specific IgE and IgG4 were measured at
baseline and week 8 for healthy volunteers and weeks 16 and 20 for peanut allergic subjects,
as was anti-Ara h 1, -Ara h 2, and -Ara h 3 IgE. In a post hoc analysis, IgE levels to native
peanut, recombinant peanut, and the modified recombinant proteins were measured using an
enzyme-linked immunosorbent assay (ELISA). Binding of the peanut-specific IgE to native
and recombinant proteins was detected with a horseradish peroxidase–labeled goat anti-
human IgE (Sigma-Aldrich) secondary antibody using ABTS substrate (KPL, Inc,
Gaithersburg, Md) and absorbance at 405 nm. IgE binding to whole modified proteins were
also assessed at baseline and week 20.
Skin Prick Testing—A SPT to peanut extract (Greer Laboratories, Lenoir, NC, USA) was
performed in healthy volunteers and peanut allergic subjects at baseline and at week 8 for
healthy volunteers and weeks 16 and 20 for peanut-allergic subjects. In addition, end-point
titration SPT was performed with the same extract in peanut allergic subjects with four serial
ten-fold dilutions of the 1:20 wt/vol peanut extract (1:20, 1:200, 1:2000, and 1:20,000) at
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baseline and at week 20, and changes were assessed by measuring the area under the curve
(AUC) calculated as the sum of the wheals at each of the 5 serial dilutions.
Basophil activation—Flow cytometry-based assessment of basophil activation /
degranulation with and without in vitro stimulation was assessed to track changes induced
by EMP-123 at baseline, week 16, and week 20 utilizing 0.25 mL of whole blood as
previously described.(22) After a 30-minute incubation, cells were fixed and shipped to the
central laboratory. Samples were then analyzed by flow cytometry for surface expression of
activation markers (CD63, CD203c and CD69).
Statistical Analysis
The sample size for this Phase 1 first-in-humans safety study was selected to be 5 healthy
volunteers and 10 peanut allergic subjects, which would provide for initial assessment of
safety parameters. If symptomatic response was sufficiently limited, this study group would
permit larger subsequent studies for further evaluations of product safety and efficacy. If no
peanut allergic subject developed significant dose-limiting allergic reactions, the upper 95%
one-sided confidence limit for this event would be 0.26. Exact 2 sample Wilcoxon tests were
used to compare baseline antibody levels of reactive and non-reactive subjects.
Results
All 5 healthy subjects tolerated all 4 doses except for diarrhea or loose stools post-dosing
occurring in two subjects. No dose adjustments were required and no immunological
changes were noted after dosing. The remainder of the results will focus on the allergic
subjects.
Baseline demographic and laboratory data for the 10 peanut allergic volunteers are presented
in Table 1. There were 6 males and 4 females (median age, 24 years). Four had a history of
asthma, the median peanut SPT wheal was 11.3 mm (range 6.5 – 18 mm), and the median
peanut IgE level was 33.3 kUA/l (range 7.2 – 120 kUA/l).
Four of the 10 subjects completed dosing without any adverse reactions. One subject
experienced rectal pruritus at the 3rd and 7th dose but completed all 13 doses and was
considered non-reactive. The remaining 5 subjects experienced adverse reactions that
prevented them from completing dosing (Table 2). Two of these reactions were categorized
as mild but, per protocol, required discontinuation of dosing. The remaining three subjects
experienced more severe reactions, including one moderate reaction at dose 12 (flushing,
pruritus, throat discomfort, and wheezing), one anaphylactic reaction at dose 9 (nausea,
diarrhea, flushing, hives, hoarseness / throat tightness), and one anaphylactic reaction at
dose 11 (abdominal pain, diarrhea, congestion, pruritus, shortness of breath, throat
tightness / hoarseness). Each of these reactions occurred within one hour of dosing.
Analyses were conducted to investigate clinical or immunologic differences between the
reactive and non-reactive subjects, as well as to assess for immunologic changes before and
after treatment (Table 3). Baseline peanut IgE levels were significantly higher for the 5
reactive subjects (median 82.4 kUA/L versus 17.2, p=0.032). Anti-Ara h 2 IgE was also
higher in the reactive subjects (43.3 vs. 8.3, P=0.03), while skin test results were similar
(p=0.88). There were no significant changes in peanut IgE from baseline to week 20
(median change −1.5 kUA/L for non-reactive subjects compared to −14.7 kUA/L for reactive
subjects). No baseline differences were found for peanut IgG4, which also did not change
significantly from baseline to week 20. However, changes after treatment were detected for
peanut endpoint titration SPT, for which the median change in AUC decreased from
baseline for all subjects to week 20 (Supplemental Table 1, −10.0 within-subject change;
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p=0.02). Basophil activation was assessed at baseline and weeks 16 and 20. The only
significant change was an increase from baseline in %CD63+ at the 0.01 µg/ml
concentration (p=0.05) (Supplemental Figure 2). There were no other trends over time or
differences between the reactive and non-reactive subjects, including measures of peanut
specific IgA and IgA2.
Additional post-hoc analyses were performed to further assess differences between reactive
and non-reactive subjects (Table 3), including standard peanut specific IgE, anti-Ara h 1, -
Ara h 2, and -Ara h 3, total IgE, and IgE against wild type recombinant peanut, native
peanut, and the modified recombinant proteins used in treatment. Aside from the differences
in anti-peanut and anti-Ara h 2 differences noted above, the only other significant
differences were detected for recombinant Ara h 2 and Ara h 3. While there were trends
toward differences in IgE to the modified recombinant proteins, these were not significant.
Discussion
EMP-123 was developed as a vaccine to induce tolerance to the dominant peanut proteins,
Ara h 1, 2 and 3, with the rationale that disruption of sequential IgE binding epitopes on
wild type peanut proteins may reduce the ability of these proteins to induce adverse allergic
responses. Additional rationale included delivery of the modified peanut proteins within an
intact cellular delivery system (i.e., E. coli) to further reduce the potential for allergic
reactions, and the use of bacteria themselves to enhance tolerance by providing antigen-
presenting cells activation factors to promote induction of Th1 immunity, and potentially
suppress antigen-specific Th2 responses. Finally, it was hypothesized that the rectal route of
administration might further enhance the development of tolerance given the rich
immunologic environment of the lower colon. Theoretically, therefore, this approach could
enhance both safety and efficacy compared to immunotherapy using intact peanut proteins,
and might also shorten the course of therapy needed to induce tolerance if larger antigen
doses could be safely administered.
Unfortunately, however, while the product appeared safe in the healthy volunteers, adverse
reactions were common in the peanut allergic subjects. Fifty percent of those participants
were unable to complete the dosing regimen. While the study stopping rules were very
stringent for this Phase 1 study, 3 of the 10 peanut allergic participants did experience
significant allergic reactions to the product. This was more likely to occur in those with
higher baseline peanut IgE levels, although these levels were not exceptionally high relative
to those encountered in routine clinical practice. Co-existent asthma did not appear to be a
factor, but this conclusion is limited by exclusion of patients with persistent asthma.
Given the marked heterogeneity of epitope recognition by peanut allergic patients (23), it
would not be surprising that individual patients may have serum IgE that recognizes as yet
unidentified epitopes, or that critical amino acids were not modified in the current EMP-123
product. Thus, while reduced IgE binding was anticipated for most patients (21), it was not
expected that the modified allergens in EMP-123 would have reduced IgE binding in all
subjects. However, the frequency and intensity of the reactions that occurred in this small
number of subjects was unexpected. Surprisingly, when analyzing IgE levels to the modified
proteins, differences were not detected between the reactive and non-reactive subjects.
However, our failure to detect these differences may simply reflect the small sample size, as
trends were noted with regard to IgE levels to the modified proteins, or that subjects were
reacting to something else in the vaccine product.
It is possible that these reactions could have been minimized or avoided if a more
conservative approach to dosing had been undertaken, potentially including slower
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escalation and daily dosing. For example, in recent oral and sublingual immunotherapy
trials, it is typical to administer doses on a daily basis and to escalate dosing over a period of
4–6 months (7, 24–25). We had anticipated that a more rapid escalation and weekly dosing
would be tolerated using this modified product, and although we do not know that a
different approach to dosing would be beneficial, it is certainly possible that it would be. We
also do not know if the rectal route of delivery added to the risk of adverse reactions due to
its highly absorptive nature.
There was no effort to assess efficacy in this Phase 1 trial, but we included several measures
to evaluate immunologic changes with treatment. No changes in peanut IgE or IgG4 were
detected. There was, however, a significant change in skin test responses measured by end
point titration, as well as basophil reactivity at the 0.01 ug concentration. Although it is
impossible to know whether these changes have any clinical significance, the SPT results
are similar to those seen in a study of peanut SLIT where modest changes in food challenge
threshold were seen after treatment (26).
In conclusion, as tested, this vaccine led to frequent and sometimes severe allergic reactions,
in spite of the clear scientific rationale and pre-clinical studies behind its development.
Future studies with this product, if any, will require alterations in the dosing scheme and / or
route of delivery. The overall approach, however, of using modified allergens for
immunotherapy, still holds great interest for all the reasons underlying the development of
this product. While other immunotherapeutic methods currently under investigation
certainly hold promise approaches that could enhance both safety and efficacy are still
highly desirable.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline demographic and laboratory data (minimum-maximum (median)) for the 10 peanut allergic subjects
Gender 6 male / 4 female
Age (yrs,median) 19 – 35 (24)
Other food allergy 10
      Tree nuts 7
      Other 3
Asthma (mild intermittent only) 4
Peanut skin test wheal (mm) 6.5 – 18 (11.3)
Peanut IgE (kUA/L) 7.2 – 120.2 (33.3)
Peanut IgE Ara h 1 (kUA/L) 4.9 – 63.3 (21.6)
Peanut IgE Ara h 2 (kUA/L) 2.9 – 119.6 (18.9)
Peanut IgE Ara h 3 (kUA/L) 0 – 14.2 (2.1)
Peanut IgG4 (mgA/L) 0.5 – 17.0 (4.7)
Peanut IgG4 Ara h 1 (mgA/L) 0.09 – 0.72 (0.26)
Peanut IgG4 Ara h 2 (mgA/L) 0.14 – 1.05 (0.24)
Peanut IgG4 Ara h 3 (mgA/L) 0.04 – 0.77 (0.08)
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Table 2








M1 120.2 no 3063 Moderate reaction at dose 12 (flushing, pruritus, throat discomfort, and wheezing);
refused epinephrine); discontinued from study per protocol.
J1 82.4 no 3063 Mild reaction (severe crampy abdominal pain) at dose 4; dose repeated and re-escalated
but had same reaction at dose 12 - discontinued study drug per protocol.
M7 90.3 yes 1750 Mild abdominal discomfort, flushing, and diarrhea after dose 9, repeated dose and
experienced mild abdominal discomfort - discontinued study drug per protocol.
J2 28.3 no 875* Anaphylaxis at dose 9 (nausea, diarrhea, flushing, hives, hoarseness / throat tightness);
given epinephrine with resolution; discontinued from study per protocol.
J3 38.2 no 3063 Anaphylaxis at dose 11 (abdominal pain, diarrhea, congestion, pruritus, shortness of
breath, throat tightness / hoarseness); treated with epinephrine with resolution;
discontinued from study per protocol.
M2 7.2 no 3063 None
M3 73.6 yes 3063 None
M4 11.2 yes 3063 None
M5 17.2 no 3063 None
M6 26.2 yes 3063 Mild rectal pruritus at 40 and 437.5 mcg doses
*
Subject J2 had one earlier dose repeated and was therefore on lower dose at dose 9 than subject M7
















































































































































   


















   















   














   













   





































   














   













   













   
































   




















   



















   



















   



















   




















   




















   




















   





































































































































































































Allergy. Author manuscript; available in PMC 2014 June 01.
